Profile data is unavailable for this security.
About the company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
- Revenue in USD (TTM)74.68m
- Net income in USD-644.76m
- Incorporated2013
- Employees600.00
- LocationRecursion Pharmaceuticals Inc41S Rio Grande StreetSALT LAKE CITY 84101United StatesUSA
- Phone+1 (302) 674-4089
- Fax+1 (302) 674-5266
- Websitehttps://www.recursion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | 0.00 | -15.84m | 1.69bn | 5.00 | -- | 5.59 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.71bn | 65.00 | -- | 3.58 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Pharvaris NV | 0.00 | -190.13m | 1.72bn | 108.00 | -- | 4.80 | -- | -- | -3.39 | -3.39 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| Relay Therapeutics Inc | 15.36m | -276.48m | 1.76bn | 192.00 | -- | 3.02 | -- | 114.64 | -1.61 | -1.61 | 0.0895 | 3.26 | 0.0206 | -- | -- | 79,979.16 | -37.05 | -35.52 | -39.04 | -37.06 | -- | -- | -1,800.46 | -2,911.42 | -- | -- | 0.00 | -- | 53.44 | -28.58 | 18.13 | -- | -26.65 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.76bn | 60.00 | -- | 6.27 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Definium Therapeutics Inc | 0.00 | -183.79m | 1.76bn | 105.00 | -- | 5.26 | -- | -- | -2.06 | -2.06 | 0.00 | 3.36 | 0.00 | -- | -- | 0.00 | -49.52 | -52.67 | -57.73 | -60.64 | -- | -- | -- | -- | -- | -- | 0.1088 | -- | -- | -- | -69.12 | -- | -- | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.83bn | 263.00 | -- | 5.78 | -- | 13.61 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.84bn | 122.00 | -- | 5.23 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.86bn | 61.00 | -- | 15.73 | -- | 29.69 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Recursion Pharmaceuticals Inc | 74.68m | -644.76m | 1.87bn | 600.00 | -- | 1.65 | -- | 25.00 | -1.48 | -1.48 | 0.167 | 2.14 | 0.0511 | -- | 2.02 | 124,468.30 | -44.12 | -43.31 | -49.84 | -49.18 | 4.99 | -- | -863.35 | -816.44 | -- | -- | 0.0162 | -- | 26.92 | 79.91 | -39.06 | -- | 2.10 | -- |
| Syndax Pharmaceuticals Inc | 172.60m | -285.42m | 1.89bn | 298.00 | -- | 28.94 | -- | 10.94 | -3.30 | -3.30 | 2.00 | 0.7394 | 0.2752 | 0.4209 | 7.57 | 579,191.30 | -45.50 | -34.74 | -55.38 | -38.78 | 95.96 | -- | -165.37 | -279.37 | 4.12 | -24.68 | 0.8418 | -- | 627.84 | 157.68 | 10.46 | -- | -- | -- |
| Celldex Therapeutics Inc | 1.55m | -258.76m | 1.93bn | 198.00 | -- | 3.65 | -- | 1,246.07 | -3.90 | -3.90 | 0.0233 | 7.92 | 0.0023 | -- | 1.14 | 7,808.08 | -37.63 | -30.06 | -40.28 | -31.85 | -- | -- | -16,737.19 | -3,299.27 | -- | -- | 0.00 | -- | -77.99 | -26.93 | -63.91 | -- | 11.83 | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.93bn | 128.00 | 51.18 | 6.04 | 45.44 | 9.38 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Soleno Therapeutics Inc | 190.41m | 20.48m | 1.95bn | 182.00 | 244.03 | 4.38 | 85.01 | 10.23 | 0.1546 | 0.1546 | 3.61 | 8.61 | 0.4256 | -- | -- | 1,046,181.00 | 4.67 | -28.03 | 5.13 | -30.82 | 98.58 | -- | 10.97 | -130.73 | 5.55 | -- | 0.0997 | -- | -- | -- | 111.64 | -- | 59.83 | -- |
Data as of Mar 04 2026. Currency figures normalised to Recursion Pharmaceuticals Inc's reporting currency: US Dollar USD
38.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 43.17m | 8.40% |
| ARK Investment Management LLCas of 31 Dec 2025 | 37.32m | 7.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 31.81m | 6.19% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 25.33m | 4.93% |
| Baillie Gifford & Co.as of 31 Dec 2025 | 23.77m | 4.62% |
| Geode Capital Management LLCas of 31 Dec 2025 | 10.93m | 2.13% |
| MIC Capital Management UK LLPas of 31 Dec 2025 | 9.64m | 1.88% |
| Amova Asset Management Americas, Inc.as of 31 Dec 2025 | 6.22m | 1.21% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 5.74m | 1.12% |
| Lingotto Investment Management LLPas of 31 Dec 2025 | 4.93m | 0.96% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
